Stock AnalizHims & Hers Health, Inc. HIMS
Medical/Nursing Services · IPO 2019 · data as of November 13, 2026
Hims & Hers Health, Inc. (HIMS) is a healthcare company listed in the US with a market value of about $4.6B. In the twelve months to September 30, 2026 it had revenue of $2.9B and net income of -$191M, a net margin of -6.7%.
Its overall Stock Analiz score is 1.8 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a price to free cash flow of 562.5, 5-year revenue growth of 74% a year, a 5-year average ROIC of -9%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 20% below the current price.
Score: 1.8 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9B | $2.3B | $1.5B | $872M | $527M | $272M | $149M | $83M |
| Net income | -$191M | $128M | $126M | -$24M | -$66M | -$108M | -$18M | -$72M |
| Free cash flow | $8M | $57M | $198M | $47M | -$34M | -$39M | -$5M | -$76M |
| EPS (diluted) | $-0.83 | $0.51 | $0.53 | $-0.11 | $-0.32 | $-0.58 | $-0.51 | $-2.07 |
| Net margin | -6.7% | 5.5% | 8.5% | -2.7% | -12.5% | -39.6% | -12.2% | -87.3% |
| ROIC | — | 5.0% | 10.0% | -6.6% | -21.7% | -32.9% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $28.31, 43% above the current price; targets range from $23.00 to $40.00; the consensus rating is “Hold”; expected EPS is $-0.91 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Hims & Hers Health stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 20% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Hims & Hers Health pay a dividend?
Not currently.
Is Hims & Hers Health a good stock to buy?
We do not give buy or sell advice. Hims & Hers Health scores 1.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.